Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SLDB Solid Biosciences

盘后交易 07-31 17:00:33 EDT

8.06

-0.43

-5.06%

盘后8.06

+0.000.00%

16:10 EDT

最高8.63	最低8.00	成交量106.06万
今开8.48	昨收8.49	日振幅7.42%
总市值7.93亿	流通市值4.11亿	总股本9,839万
成交额861.05万	换手率2.08%	流通股本5,104万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SLDB","market":"US","secType":"STK","nameCN":"Solid Biosciences","latestPrice":8.06,"timestamp":1785528000000,"preClose":8.49,"halted":0,"volume":1060556,"hourTrading":{"tag":"盘后","latestPrice":8.06,"preClose":8.06,"latestTime":"16:10 EDT","volume":5676,"amount":45817.267980000004,"timestamp":1785528604693,"change":0,"changeRate":0,"amplitude":0.003722},"delay":0,"changeRate":-0.05064782096584213,"floatShares":51039700,"shares":98391314,"eps":-1.954674,"marketStatus":"盘后交易","change":-0.43,"latestTime":"07-31 17:00:33 EDT","open":8.48,"high":8.63,"low":8,"amount":8610525,"amplitude":0.074205,"askPrice":8.49,"askSize":200,"bidPrice":8,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.954674,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785542400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1516942800000,"exchange":"NASDAQ","adjPreClose":8.49,"preHourTrading":{"tag":"盘前","latestPrice":8.72,"preClose":8.49,"latestTime":"08:11 EDT","volume":925,"amount":7974.440262499999,"timestamp":1785499890357,"change":0.23,"changeRate":0.027091,"amplitude":0.047114},"postHourTrading":{"tag":"盘后","latestPrice":8.06,"preClose":8.06,"latestTime":"16:10 EDT","volume":5676,"amount":45817.267980000004,"timestamp":1785528604693,"change":0,"changeRate":0,"amplitude":0.003722},"volumeRatio":1.000996,"impliedVol":1.7345,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/SLDB","defaultTab":"news","newsList":[{"id":"1147512603","title":"Solid Biosciences与Nanomosaic宣布达成联合营销协议，共促基因疗法递送与分析技术发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1147512603","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147512603?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:01","pubTimestamp":1780398119,"startTime":"0","endTime":"0","summary":"Solid Biosciences与Nanomosaic近日共同宣布，双方已签署一项联合营销协议，旨在携手推进基因治疗领域的递送技术与分析方案的进步。这一合作将整合双方的专业优势，共同开发并推广创新的解决方案，以应对基因疗法在精准递送与高效分析方面所面临的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151595680","title":"Solid Biosciences启动SGT-003治疗杜氏肌营养不良症的三期临床试验，完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1151595680","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151595680?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:03","pubTimestamp":1778155406,"startTime":"0","endTime":"0","summary":"生物技术公司Solid Biosciences（股票代码：SLDB）宣布，其在研基因疗法SGT-003针对杜氏肌营养不良症（DMD）的三期临床试验“IMPACT Duchenne”已完成首例患者给药。这标志着该疗法临床开发进入关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185009877","title":"Solid Biosciences宣布SGT-003获欧盟委员会授予杜氏肌营养不良症孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1185009877","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185009877?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:02","pubTimestamp":1777377757,"startTime":"0","endTime":"0","summary":"生物技术公司Solid Biosciences近日宣布，其针对杜氏肌营养不良症研发的基因治疗候选药物SGT-003，已正式获得欧盟委员会颁发的孤儿药资格认定。这一认定标志着该疗法在欧盟地区药物开发进程中的重要监管进展。SGT-003作为该公司基因治疗管线的重要候选药物，此次获得欧盟监管机构的认可，为其在欧洲市场的战略布局奠定了坚实基础。该认定将加速推进SGT-003在全球范围内的临床开发计划，为杜氏肌营养不良症患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158258589","title":"Solid Biosciences提交转售说明书 股东拟最高减持130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1158258589","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158258589?lang=zh_cn&edition=full","pubTime":"2026-03-20 05:05","pubTimestamp":1773954314,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露文件，生物科技公司Solid Biosciences已提交转售说明书，公司某持股股东计划最高转售130万股普通股。\n此次备案为后续市场交易提供法律依据，转售规模约占公司流通股本的一定比例。文件显示该交易将通过公开市场渠道进行，具体出售时间与价格将根据市场情况确定。\n作为专注基因疗法研发的生物制药企业，Solid Biosciences近期股价波动较大。本次股东减持计划可能对二级市场流动性产生一定影响，投资者需关注后续持股变动情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131831762","title":"Solid Biosciences公布2025年第四季度及全年财报并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1131831762","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131831762?lang=zh_cn&edition=full","pubTime":"2026-03-20 04:13","pubTimestamp":1773951193,"startTime":"0","endTime":"0","summary":"Solid Biosciences近日披露了2025年第四季度及全年的财务业绩报告，同时分享了公司最新的业务动态。此次公布涵盖了公司在财务表现和战略推进方面的关键信息，展现了企业当前的发展态势与未来规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167979938","title":"Solid Biosciences计划于2026年上半年与FDA再次会晤，寻求SGT-003加速审批路径指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1167979938","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167979938?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:02","pubTimestamp":1773248534,"startTime":"0","endTime":"0","summary":"Solid Biosciences（SLDB）近日披露，公司计划在2026年上半年与美国食品药品监督管理局（FDA）举行后续会议，旨在就基因疗法SGT-003可能适用的加速批准路径获取进一步指导。\n此次会议将聚焦于探讨SGT-003是否符合加速审批的资格标准，以及需要满足哪些监管要求。公司希望通过与FDA的深入沟通，明确后续临床开发及申报策略，为这款针对杜氏肌营养不良症（DMD）的潜在疗法铺平道路。\n加速审批路径通常允许基于替代终点或中间临床终点提前批准用于严重疾病的药物，以更快满足患者需求。Solid Biosciences此举显示出其积极推进SGT-003研发进程的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134708202","title":"Solid Biosciences 公布 SGT-003 治疗结果：观察到强劲的微肌营养不良蛋白表达与肌肉结构改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1134708202","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134708202?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:02","pubTimestamp":1773248533,"startTime":"0","endTime":"0","summary":"在近期一项重要的研究进展中，Solid Biosciences 公司宣布，其基因治疗候选药物 SGT-003 在临床前研究中显示出积极效果。数据显示，经 SGT-003 治疗后，实验模型内出现了显著的微肌营养不良蛋白表达，其水平远超预期基准。同时，组织学分析证实，受试肌肉的完整性得到明显改善，纤维化程度减轻，肌肉组织结构更为健康。这些发现为 SGT-003 作为杜氏肌营养不良症的潜在疗法提供了有力的科学依据，标志着公司在推进该创新疗法方面取得了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168057909","title":"Solid Biosciences公司SGT-003在40名参与者中总体耐受性良好，安全性特征令人鼓舞","url":"https://stock-news.laohu8.com/highlight/detail?id=1168057909","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168057909?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:02","pubTimestamp":1773248531,"startTime":"0","endTime":"0","summary":"Solid Biosciences公司宣布，其候选疗法SGT-003在一项涉及40名参与者的研究中展现出良好的耐受性。初步数据显示，该疗法的安全性特征积极，为后续临床开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618393513","title":"Solid Biosciences Inc.盘中异动 早盘快速拉升6.18%报7.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618393513?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:30","pubTimestamp":1773063045,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时30分，Solid Biosciences Inc.股票出现波动，股价大幅拉升6.18%。截至发稿，该股报7.17美元/股，成交量18.2204万股，换手率0.23%，振幅0.89%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Relmada Therapeutics, Inc.、Xenon制药、Biohaven Ltd.涨幅较大，Relmada Therapeutics, Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为29.75%、18.74%、13.13%，振幅较大的相关个股有Aditxt, Inc.、Uniqure N.V.、Scinai Immunotherapeutics Ltd，振幅分别为13.06%、10.58%、8.10%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921304597ab23c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921304597ab23c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614197065","title":"Solid Biosciences Inc.盘中异动 早盘股价大涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614197065","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614197065?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:54","pubTimestamp":1772031286,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日22时54分，Solid Biosciences Inc.股票出现异动，股价大幅上涨5.24%。截至发稿，该股报6.50美元/股，成交量15.0151万股，换手率0.19%，振幅4.94%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225225446a4c7b6ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225225446a4c7b6ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612143414","title":"Solid Biosciences Inc.盘中异动 急速下跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612143414","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612143414?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:41","pubTimestamp":1771339315,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时41分，Solid Biosciences Inc.股票出现波动，股价急速下跌5.17%。截至发稿，该股报5.87美元/股，成交量6.3449万股，换手率0.08%，振幅4.52%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Polaryx Therapeutics, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 、Biovie Inc C/Wts 08/08/2030涨幅较大，Ernexa Therapeutics Inc.、Quince Therapeutics, Inc.、Moolec Science Sa较为活跃，换手率分别为66.89%、35.36%、32.83%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Xtl生物制药、Eyepoint, Inc.，振幅分别为23.24%、18.82%、18.62%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217224155a7047371&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217224155a7047371&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611228112","title":"Solid Biosciences Inc.盘中异动 早盘快速上涨5.10%报6.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611228112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611228112?lang=zh_cn&edition=full","pubTime":"2026-02-14 00:09","pubTimestamp":1770998948,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日00时09分，Solid Biosciences Inc.股票出现波动，股价大幅拉升5.10%。截至发稿，该股报6.39美元/股，成交量16.5095万股，换手率0.21%，振幅5.43%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为2.19%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Phio Pharmaceuticals Corp.涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为4349.42%、285.26%、196.55%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Quince Therapeutics, Inc.，振幅分别为114.94%、65.10%、38.85%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021400090897a622f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021400090897a622f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610662279","title":"Solid Biosciences Inc.盘中异动 早盘快速上涨5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610662279?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:48","pubTimestamp":1770734919,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时48分，Solid Biosciences Inc.股票出现波动，股价大幅拉升5.42%。截至发稿，该股报7.23美元/股，成交量12.5455万股，换手率0.16%，振幅5.17%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为1474.33%、731.40%、652.11%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Ernexa Therapeutics Inc C/Wts  04/02/2030，振幅分别为58.92%、31.58%、28.57%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224839a6eb0441&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210224839a6eb0441&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151781838","title":"Solid Biosciences就SGT-003基因疗法治疗杜氏肌营养不良症与FDA达成C类会议积极共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1151781838","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151781838?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:05","pubTimestamp":1770642307,"startTime":"0","endTime":"0","summary":"Solid Biosciences（纳斯达克代码：SLDB）近日宣布，其针对杜氏肌营养不良症（DMD）研发的SGT-003基因疗法，在与美国食品药品监督管理局（FDA）举行的C类会议中获得了积极反馈。这一关键进展为该项目后续的临床开发计划清除了重要监管障碍。\nFDA对SGT-003现有的临床前数据包表示了认可，并就下一阶段的临床试验设计提供了建设性指导。此次积极的监管互动标志着SGT-003项目向前迈出了实质性的一步，增强了其治疗DMD这一严重遗传性疾病的潜力。公司计划基于此次会议反馈，加快推进SGT-003的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609808558","title":"Solid Biosciences Inc.盘中异动 股价大跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609808558","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609808558?lang=zh_cn&edition=full","pubTime":"2026-02-06 03:47","pubTimestamp":1770320875,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日03时47分，Solid Biosciences Inc.股票出现异动，股价大幅下跌5.44%。截至发稿，该股报6.17美元/股，成交量82.9723万股，换手率1.06%，振幅7.21%。Solid Biosciences Inc.股票所在的生物技术行业中，整体跌幅为1.26%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Liminatus Pharma, Inc.、Cytomed Therapeutics Limited涨幅较大，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Propanc Biopharma, Inc.较为活跃，换手率分别为2009.90%、1240.89%、261.37%，振幅较大的相关个股有Aim Immunotech Inc.、Liminatus Pharma, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为67.29%、66.50%、57.78%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602060347559540087d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602060347559540087d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605477800","title":"Solid Biosciences Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605477800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605477800?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:58","pubTimestamp":1769093900,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日22时58分，Solid Biosciences Inc.股票出现异动，股价急速拉升5.00%。截至发稿，该股报6.47美元/股，成交量10.966万股，换手率0.14%，振幅5.03%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.74%。其相关个股中，60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Cabaletta Bio, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为10751.05%、357.62%、272.63%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Greenwich Lifesciences, Inc.，振幅分别为131.00%、69.40%、21.53%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122225820953defd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122225820953defd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603985947","title":"Solid Biosciences Inc.盘中异动 大幅拉升5.04%报5.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603985947?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:16","pubTimestamp":1768403806,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日23时16分，Solid Biosciences Inc.股票出现波动，股价急速上涨5.04%。截至发稿，该股报5.42美元/股，成交量10.4137万股，换手率0.13%，振幅4.46%。Solid Biosciences Inc.股票所在的生物技术行业中，整体涨幅为0.01%。Solid Biosciences Inc.公司简介：Solid Biosciences Inc 是一家生命科学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114231646a71ac900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114231646a71ac900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117152768","title":"Solid Biosciences公布2026年展望，强调神经肌肉与心脏管线进展及新一代衣壳AAV-SLB101的扩大可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1117152768","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117152768?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:16","pubTimestamp":1768338994,"startTime":"0","endTime":"0","summary":"Solid Biosciences（纳斯达克代码：SLDB）近日发布了其2026年战略展望，重点突出了公司在神经肌肉疾病和心脏疾病治疗管线方面取得的显著进展。报告同时披露，公司下一代基因治疗衣壳AAV-SLB101的可及性将进一步扩大，为更多患者带来希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129514473","title":"Solid Biosciences旗下SGT-212双路径基因疗法获FDA孤儿药认定 用于治疗弗里德赖希共济失调","url":"https://stock-news.laohu8.com/highlight/detail?id=1129514473","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129514473?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252619,"startTime":"0","endTime":"0","summary":"Solid Biosciences宣布，其研发的SGT-212双路径基因疗法已获得美国食品药品监督管理局授予的孤儿药认定，适应症为弗里德赖希共济失调。获得该认定后，Solid Biosciences将在药物开发和商业化过程中享受一系列政策支持，包括临床试验费用税收抵免、豁免部分申请费用以及上市后七年的市场独占权。弗里德赖希共济失调是一种遗传性神经系统疾病，目前尚无有效治疗方法。SGT-212通过双路径给药机制，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157703345","title":"Solid Biosciences：完成1B期Falcon试验首名受试者给药，初步数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1157703345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157703345?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:16","pubTimestamp":1768252580,"startTime":"0","endTime":"0","summary":"Solid Biosciences（SLDB）宣布，其1B期Falcon临床试验已完成对首位参与者的给药程序。该试验旨在评估其在研疗法的安全性与有效性。\n公司预计将于2026年下半年获得并公布这项研究的初步数据。此次进展标志着该药物临床开发计划中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLDB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.solidbio.com","stockEarnings":[{"period":"1week","weight":0.0639},{"period":"1month","weight":-0.1502},{"period":"3month","weight":0.1907},{"period":"6month","weight":0.3142},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.5053}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Solid Biosciences Inc.前称是“SOLID Ventures Management, LLC”，成立于2013年3月，最初是作为一家特拉华州有限责任公司成立的。该公司是一家生命科学公司，专注于推进当前和未来基因治疗候选药物组合，该公司将其统称为候选药物，包括用于治疗杜氏肌营养不良症的SGT-003，或Duchenne，用于治疗儿茶酚胺能多形性室性心动过速（CPVT）的SGT-501，以及用于治疗心脏和疾病的额外资产，处于不同的发展阶段，投资水平不同。该公司正在推进涉及罕见神经肌肉和心脏疾病的多样化管道，汇集科学、技术、疾病管理和护理方面的专家。以患者为中心，由直接受到Duchenne影响的人创立，该公司的使命是改善患有这些毁灭性疾病的患者的日常生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.034906},{"month":2,"riseRate":0.444444,"avgChangeRate":0.028361},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100699},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016391},{"month":5,"riseRate":0.555556,"avgChangeRate":0.036713},{"month":6,"riseRate":0.555556,"avgChangeRate":0.126637},{"month":7,"riseRate":0.444444,"avgChangeRate":0.059029},{"month":8,"riseRate":0.375,"avgChangeRate":-0.007542},{"month":9,"riseRate":0.375,"avgChangeRate":-0.06872},{"month":10,"riseRate":0.25,"avgChangeRate":-0.04082},{"month":11,"riseRate":0.625,"avgChangeRate":-0.055728},{"month":12,"riseRate":0.5,"avgChangeRate":0.250324}],"exchange":"NASDAQ","name":"Solid Biosciences","nameEN":"Solid Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Solid Biosciences(SLDB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Solid Biosciences,SLDB,Solid Biosciences股票,Solid Biosciences股票老虎,Solid Biosciences股票老虎国际,Solid Biosciences行情,Solid Biosciences股票行情,Solid Biosciences股价,Solid Biosciences股市,Solid Biosciences股票价格,Solid Biosciences股票交易,Solid Biosciences股票购买,Solid Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Solid Biosciences(SLDB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Solid Biosciences(SLDB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}